Follow-On Brand Drugs Could Draw FTC Anticompetitive Scrutiny
This article was originally published in The Pink Sheet Daily
Executive Summary
Introduction of certain types of successor drugs as the original product nears patent expiration has "caught the attention" of individuals at FTC, Commissioner Harbour tells BIO annual conference. A company's history and methods of engaging in this practice to blunt generic competition could open it up to agency scrutiny, she says.
You may also be interested in...
Nexium Is Part Of Anti-Competitive Plan To Thwart Generic Prilosec, Retailer Suit Against AstraZeneca Says
Walgreen’s, Eckerd and Kroger are among the retailers filing suit against AstraZeneca over the launch of the Prilosec follow-on Nexium.
Nexium Is Part Of Anti-Competitive Plan To Thwart Generic Prilosec, Retailer Suit Against AstraZeneca Says
Walgreen’s, Eckerd and Kroger are among the retailers filing suit against AstraZeneca over the launch of the Prilosec follow-on Nexium.
AstraZeneca’s New Head Of Strategic Planning & Business Development John Goddard: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
AstraZeneca looking to improve how it manages deals, Goddard says.